# A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

> **NCT06387420** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 180 (estimated)

## Conditions studied

- ACUTE MYELOID LEUKEMIA; AML

## Interventions

- **DRUG:** AK117
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06387420
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06387420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06387420, "A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06387420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*